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Abstract
Background: Anesthesia induction and maintenance with propofol can be guided by target-controlled infusion (TCI) systems using
pharmacokinetic (Pk) models. Physiological variables, such as changes in cardiac output (CO), can influence propofol pharmacoki-
netics. Knee-chest (KC) surgical positioning can result in CO changes.
Objectives: This study aimed to evaluate the relationship between propofol plasma concentration prediction and CO changes after
induction and KC positioning.
Methods: This two-phase prospective cohort study included 20 patients scheduled for spinal surgery. Two different TCI anesthesia
protocols were administered after induction. In phase I (n = 9), the loss of consciousness (LOC) concentration was set as the propofol
target concentration and CO changes following induction and KC positioning were quantified. In phase II (n = 11), based on data
from phase I, two reductions in the propofol target concentration on the pump were applied after LOC and before KC positioning.
Propofol plasma concentrations were measured at different moments in both phases: after induction and after KC positioning.
Results: Schnider Pk model showed a good performance in predicting propofol concentration after induction; however, after KC
positioning, when a significant drop in CO occurred, the measured propofol concentrations were markedly underestimated. In-
tended reductions in the propofol target concentration did not attenuate HD changes. In the KC position, there was no correlation
between the propofol concentration estimated by the Pk model and the measured concentration in plasma, as the latter was much
higher (P = 0.013) while CO and BIS decreased significantly (P < 0.001 and P = 0.004, respectively).
Conclusions: Our study showed that the measured propofol plasma concentrations during the KC position were significantly un-
derestimated by the Schnider Pk model and were associated with significant CO decrease. When placing patients in the KC position,
anesthesiologists must be aware of pharmacokinetic changes and, in addition to standard monitoring, the use of depth of anesthe-
sia and cardiac output monitors may be considered in high-risk patients.
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1. Background
Anesthesia induction and maintenance with propo-
fol can be guided by target-controlled infusion (TCI) sys-
tems that incorporate a pharmacokinetic (Pk) model into
a computer-controlled pump, allowing for intravenous
anesthetics titration and targeting plasma and effect-site
drug concentrations (1, 2). However, propofol pharmacoki-
netics can be influenced by changes in physiological vari-
ables, such as cardiac output (CO), as propofol is a high-
clearance drug. In addition, an increase in the propofol
plasma concentration could also result in hemodynamic
(HD) changes (3-7). These HD variations can modify the
TCI modeling ability to predict propofol concentrations (8)
such that up to a 60% precision error can occur as the great-
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est bias after induction in the early maintenance phase (9).
Patients’ positioning in the knee-chest (KC) position
(Figure 1) following anesthesia induction further reduces
venous return and CO (10, 11). Physiological changes and
complications associated with surgical positions, such as
the prone and KC positions, have been studied extensively
(12, 13).
Researchers previously observed that patients in the
prone position required less propofol than those in the
supine position. In the present study, it was hypothe-
sized that predicted propofol effect-site (Ce) and predicted
plasma concentrations (Cp) would not be accurate when
these HD changes occur, especially after KC positioning (4,
5, 14). It was also hypothesized that applying two different
TCI anesthesia protocol reductions in propofol infusion,
one performed after induction and the other one before
positioning, would reduce the prediction error and atten-
uate the CO changes.
2. Objectives
The aim of this study was to quantify the variations
in propofol plasma concentrations (Cm), both after induc-
tion and after KC positioning, and correlate them with Cp
by the Schnider Pk model. CO was continuously measured
with a minimally invasive CO monitor, LiDCO rapid® (15-17)
(LiDCO Ltd., Cambridge, UK).
3. Methods
After obtaining the REB approval and written informed
consent, we recruited consecutive neurosurgical patients
scheduled for lumbar spinal surgery in the KC position. A
two-phase prospective observational study was conducted.
Figure 1. KC surgical position, a variant from the prone position
In the first set of patients (phase I), propofol plasma con-
centrations were measured and compared with concentra-
tions predicted by the Schnider Pk model and the changes
in CO following induction and KC positioning were quan-
tified. In the second set of patients (phase II), based on
the data from the first set of patients, two propofol target
concentration reductions were planned immediately after
anesthesia induction and before positioning.
Propofol plasma concentrations were also measured
and compared with predicted and the changes in CO fol-
lowing induction and KC positioning were also quantified,
as done in phase I. The exclusion criteria included patients
with severe ischemic heart disease, congestive heart fail-
ure, atrial fibrillation or flutter, body mass index (BMI) > 35
kg.m-2, dementia, history of drug abuse or addiction, and
preoperative midazolam. A careful physical examination
was performed on each patient to exclude potentially diffi-
cult airway and ischemic peripheral arterial disease.
3.1. Anesthesia Protocol
A crystalloid intravenous infusion at 400 mL.h-1 was
initiated once patients arrived in the operating room,
which continued until the end of anesthesia induction
and maintained at 200 mL.h-1 throughout the surgery. Pa-
tients received American Society of Anesthesiologists (ASA)
standard monitoring, including depth of anesthesia mon-
itoring with bispectral indexTM (BISTM brain monitoring,
Medtronic, USA) and neuromuscular block monitoring
with the train of four stimulations on the right hand. Be-
fore induction, a left radial artery catheter was placed with
local anesthesia to measure invasive blood pressure and
LiDCO rapid® was connected to collect CO and other hemo-
dynamic parameters every second. This device used the
same algorithm as the LIDCO plus® system, but it required
neither lithium dilution nor calibration, as it used nomo-
grams based on patients biometric parameters to estimate
cardiac output and stroke volume. In a separate com-
puter, RugLoopII© software (DEMED website, Temse, Bel-
gium) was used to drive remifentanil and propofol pumps
(AlarisTM Asena, BD, UK) and to collect data every five sec-
onds while connected to the patient monitor (Aisys®, GE
Healthcare, USA). At this moment, the first blood sam-
ple, called “Baseline”, which was free of drugs, was col-
lected and all pharmacological and HD parameters were
recorded. Anesthesia induction commenced with remifen-
tanil (20 µg.mL-1) by the TCI mode to achieve a predicted
effect-site target concentration (Ce) of 2.5 ng.mL-1 (Minto
pharmacokinetic model). Propofol (1%) was then started at
200 mL.h-1 in the TCI view until the loss of consciousness
(LOC). The LOC was considered when the patient failed to
open the eyes following name-calling and tapping on the
forehead. At the moment of LOC, propofol predicted effect-
site concentration (Ce) was noted from RugLoopII© soft-
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ware. The propofol protocol in patients from P1 and P2 was
different, as explained in detail in the following.
3.2. Experimental Protocol
3.2.1. Phase I (P1)
After LOC, the propofol concentration was switched
from the TCI view to the TCI mode with Schnider Pk model
at a target concentration equal to the Ce at LOC. Tracheal
intubation was accomplished following neuromuscular
blocking drug administration (rocuronium 0.6 mg.kg-1)
and patients’ lungs were mechanically ventilated with O2
and air mixture to achieve SpO2 of > 98%, tidal volume of 8
mL.kg-1, and the respiratory rate adjusted to normocapnia.
Remifentanil Ce was reduced to 1 ng.mL-1 until surgical in-
cision. Anesthesia maintenance was guided by BISTM (40-
60) and HD parameters by the anesthesiologist. The sec-
ond blood sample was collected 10 min after LOC and then
patients were positioned in the KC position carefully and
using a ProneView® platform for the head. The third blood
sample was collected and parameters were registered 10
minutes after performing the KC position before incision
(Figure 2). At this point, phase I of the study was completed.
3.2.2. Phase II (P2)
After LOC, the propofol concentration was switched
from the TCI view to the TCI mode at a Ce target lower than
Ce at LOC, calculated using a formula described in detail in
supplementary file Appendix 1, which relates the Ce of LOC
with the Ce that results in maintaining BIS between 40 and
60.
Tracheal intubation and ventilation settings were sim-
ilar to phase I. Remifentanil Ce was changed to 1 ng.mL-1
until surgical incision. The second blood sample was col-
lected 10 minutes after LOC. A second reduction of propofol
Ce was performed with the same magnitude as the CO vari-
ation observed in phase I patients and 2 minutes later, the
third blood sample was collected. Afterward, patients were
placed in the KC position as described in phase I. Ten min-
utes after KC positioning and before incision, the fourth
blood sample was collected (Figure 3). At this point, phase
II of the study was completed.
3.3. Plasma Propofol Sampling
During the study period, 3 mL arterial blood sam-
ples were collected from the left radial artery into hep-
arin containing tubes for propofol and propofol metabo-
lites quantification in the plasma according to the pro-
tocol. The propofol plasma concentration and its free
metabolites were determined by gas chromatography
mass-spectrometry with some adjustments (18, 19).
The accuracy and bias of model predictions were cal-
culated from differences between propofol Cm and Cp for
each individual patient expressed as the prediction error
(PE) (3), median prediction error (MDPE), and median ab-
solute performance error (MDAPE). An acceptable perfor-
mance was characterized by MDPE of less than 20% (-20 to
20%) and MDAPE of 20% - 40%. A model is most accurate
when the values of MDPE and MDAPE are close to zero. In
TCI, the typical accepted values are 10% to 20% for bias and
around 30% for accuracy (20).
3.4. Data Analysis
Data were collected using LiDCO rapid® and
RugLoopII© software that gathered data independently
and with different sampling frequencies; therefore, syn-
chronization between data was mandatory for this study.
Dedicated software was developed in Matlab® for the
interface. For data analysis, one-minute duration windows
were considered around each of the above-defined study
moments and the average of the observed values was
computed for each window. The statistical analysis was
considered as a full factorial model in a two-way mixed
ANOVA analysis used to compare the mean differences
of the measured variables, considering the main effect
“Moment” (within-subjects: same individual at different
moments), the main effect “Phase” (between-subjects:
different individuals, a group compared to another) and
their interactions “Moment × Phase”. A P value of < 0.05
was considered statistically significant. Further post hoc
testing (ANOVA and t-test with Bonferroni correction)
was conducted to compare “Moments” and “Phases”. The
results were expressed as mean± standard deviation (SD).
All statistical analyses were conducted in SPSS® software V.
25 (IBM, New York, USA).
4. Results
Twenty patients (9 in phase I and 11 in phase II) were in-
cluded in this study. Patients’ demographic data are pre-
sented in Table 1.
Data concerning the drugs used, HD parameters, and
BIS values are reported in Table 2. In phase I, there were
no protocolled propofol target reductions; thus, propofol
Ce target concentrations were manually modified by the
anesthesiologist, guided by BIS and HD parameters (Figure
2). Propofol Ce and Cp were statistically different between
all moments (P < 0.001) but measured propofol did not
show any differences (Table 2).
There were significant HD changes after anesthesia in-
duction and after KC positioning with respect to the base-
line in both phases (Figure 4). In phase I, CO fell by 25.6%
after induction and 38.4% after KC position, compared to
the baseline.
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Anaesthesia induction: 
Ce remifentanil,2.5 ng.ml-1
propofol 200mLh-3 until 
LOC
Propofol maintenance 
dosis: 
Propofol = LOC Ce. BIS and 
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Figure 2. Relationship between propofol effect-site concentration (Ce) (µg.mL-1) and moments of the study (time) in phase I (baseline, SP1, and KC). HD, hemodynamic; LOC,
loss of consciousness; KC, knee-chest; SP1, supine.
Table 1. Demographics and Baseline Values of the Subjects in Phase I and Phase IIa
Characteristics Phase I Phase II
Age, y 49.3± 8.7 59.7± 13.5
Sex (f/m) 6/3 6/5
Height, cm 161.6± 9.0 167.8± 12.4
Weight, kg 70.9± 13.9 77.3± 11.6
Body Mass Index, kg.m-2 27.0± 3.5 27.4± 3.0
ASA classification I/II 3/6 2/9
Cardiac output (baseline), L.min-1 7.4± 1.8 7.2± 2.3
Propofol Ce at LOC,µg.mL-1 5.03± 0.75 4.34± 1.52
Time to LOC, min 3.76± 0.80 3.05± 1.22
Abbreviations: ASA, American Society of Anesthesiologists; LOC, loss of con-
sciousness; Propofol Ce, propofol effect-site concentration.
aValues are expressed as No. or mean± SD.
In phase II, after induction, propofol target Ce was set
at a value below the Ce at LOC, based on the formula pre-
sented earlier in methods. The average decrease in propo-
fol Ce following LOC was 27.5%, with a maximum of 43%
(prop Ce LOC = 7.0µg.mL-1) and a minimum of 19% (prop Ce
LOC = 2.7 µg.mL-1). The second reduction in propofol was
performed in all patients that was equal to the CO reduc-
tion measured in patients from the phase I following KC
positioning (17.2%) (Figure 3). Propofol Ce and Cp were sta-
tistically different between all moments, except between
SP2 and KC moment (Table 2). Measured propofol showed
a statistical difference between SP2 and KC moment (P =
0.013).
In phase II, despite propofol Ce reductions, CO reduced
significantly from baseline 46.9%, after induction 19.8%
and after KC position 31% (Figure 4). From moment SP1 to
moment SP2, HD parameters did not vary.
In both phases, there was no statistical association be-
tween CO changes and age, weight, gender, baseline CO,
and propofol Ce at LOC (P > 0.05). A correlation was
found between baseline CO and propofol requirements
for LOC (propofol infused volume until LOC), with statis-
tical significance in phase II (r = 0.76; P = 0.006). Be-
tween phases, there were significant differences in propo-
fol Ce (P = 0.005) and propofol Cp (P = 0.015) at the SP1 mo-
ment. Propofol infused volume was statistically different
between all moments and between phases, except for LOC.
A total of 71 arterial blood samples were obtained,
propofol concentrations were measured, and the pre-
dicted error was calculated for each patient, as shown in
Table 3.
At the SP1 moment, there were no differences between
4 Anesth Pain Med. 2019; 9(5):e96829.
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Figure 3. Relationship between propofol effect-site concentrations (Ce) (µg.mL-1) and moments of the study (time) in phase II (baseline, SP1, SP2 and KC). HD, hemodynamic;
LOC, loss of consciousness; KC, knee-chest; SP1, supine; SP2, supine after the second reduction in propofol infusion.
Table 2. Drug Data, Cardiac Output, and BIS Values for Each Moment and Each Phasea , b
Drugs Data and
Variables (Units)
Phase I (N = 9) Phase II (N = 11) Two-Way ANOVA (P Value)
Baseline SP1 KC Baseline SP1 SP2 KC Moment Phase Moment× Phase
Propofol (µg.mL-1 )
Ce 5.03± 0.75 (LOC) 3.84± 0.63c 2.53± 0.79e 4.34± 1.52 (LOC) 2.92± 0.64c 2.47± 0.57 2.20± 0.51e < 0.001* 0.054 0.352
Cp - 3.83± 0.74 2.48± 0.86e - 2.97± 0.68 2.46± 0.58 2.24± 0.58e < 0.001* 0.06 0.083
Cm - 3.61± 1.14 3.31± 2.11 - 2.96± 0.81 2.68± 0.72 3.90± 1.90f 0.455 0.961 0.162
Remifentanil (ng.mL-1 )
Ce - 2.36± 0.42 1.11± 0.35e - 1.85± 0.66 1.12± 0.20 1.15± 0.48e < 0.001* 0.132 0.107
Propofol Inf. volume
(mL)
12.46± 2.44 (LOC) 22.53± 4.09c 37.09± 8.07d , e 9.63± 4.09 (LOC) 15.86± 6.10c 19.36± 6.71 27.15± 8.63d , e , f < 0.001* 0.014* 0.034*
BIS 94.0± 2.2 61.8± 15.2c 42.3± 15.1e 95.3± 2.6 49.9± 9.8c 46.5± 7.5 37.7± 8.7d , e < 0.001* 0.056 0.165
Cardiac output
(L.min-1 )
7.4± 1.8 5.4± 1.3c 4.4± 1.2d 7.2± 2.3 5.6± 1.6c 5.6± 1.7 3.9± 1.9d , e < 0.001* 0.867 0.514
Abbreviations: Ce, effect-site concentration; Cm, measured plasmatic concentration; Cp, predicted plasmatic concentration; Inf., Infused; LOC, loss of consciousness; KC, knee-chest; SP1, supine; SP2, supine after the second reduction in
propofol infusion.
a Values are expressed as mean± SD.
b The superscripts c, d, e, and f indicate significant differences (5% level) on repeated measures ANOVA post hoc pairwise testing with Bonferroni correction (*).
c Significant differences between Baseline and SP1.
d Significant differences between Baseline and KC;
e Significant differences between SP1 and KC;
f Significant differences between SP2 and KC.
Cp and Cm (P = 0.559) and there was a statistical correlation
between them (r = 0.640; P = 0.002). At the KC moment,
there was an underestimation of propofol plasma concen-
trations from the Pk model in both phases (34% in phase
I and 74% in phase II) (Figure 5). Cp and Cm were statisti-
cally different (P = 0.005) and there was no statistical corre-
lation between them (r = 0.374; P = 0.104). In both phases,
BIS values did not differ between phases (P = 0.165) (Table
2). There were no cases of patient awareness. Linear regres-
sion analysis revealed no statistically significant relation-
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Figure 4. HD changes (cardiac output, mean arterial pressure, stroke volume, and
systemic vascular resistance variation) in phase I and phase II.
ship between BIS values and propofol Cm or BIS values and
cardiac output at any moment.
5. Discussion
In the present study, a propofol TCI system with
Schnider Pk model was used to drive a propofol pump that
showed a marked underestimation of plasma propofol lev-
els in patients placed in the KC position. The study also
showed that the KC position was associated with signif-
icant hemodynamic changes, as a reduction in CO from
baseline was observed (Figure 4). After induction, the
Schnider Pk model showed a good performance in Cp pre-
diction (Table 3). Also, there was a statistical correlation be-
tween Cp and Cm. In the KC position, when the greatest
Table 3. Performance Analysis of the Propofol Schnider Pk Model Expressed in Me-
dian Prediction Error (MDPE) and Median Absolute Performance Error (MDAPE) for
Each Moment and Phase (%)
Moments
Propofol Pk Model Performance (%)
MDPE MDAPE
Phase I
SP1 -6% (-49 to 20) 15% (1 to 49)
KC 28% (-35 to 114) 35% (6 to 114)
Phase II
SP1 13% (-43 to 45) 20% (4 to 45)
SP2 18% (-45 to 56) 32% (0 to 56)
KC 48% (-44 to 270) 48% (6 to 270)
Abbreviations: KC, knee-chest; SP1, supine; SP2, supine after the second reduc-
tion in propofol infusion.
CO reduction occurred, Schnider Pk model performance
was not accurate, as propofol Cp was not correlated with
Cm and it was markedly underestimated by 34% in phase
I and 74% in phase II. Also, in the KC position, the MDPE
and MDAPE values calculated at this moment did not show
a good performance.
In phase II, between moment SP2 and moment KC,
when propofol Cp and propofol Ce concentrations were
unchanged and the only intervention performed on pa-
tients was KC positioning, it was observed an increase in
the measured propofol concentrations (P = 0.013) and a de-
crease in BIS values (P = 0.004) (Figure 5).
The influence of CO on the pharmacokinetic models to
predict propofol plasma concentrations during TCI had al-
ready been discussed by some authors (6). It can be spec-
ulated that the difference between the predicted and mea-
sured propofol concentrations in patients with lower CO
is most likely related to a decrease in total propofol clear-
ance, but further data are still needed to correlate CO or
liver blood flow and plasma clearance of propofol. Upton
et al. (14) reported an inverse relationship between CO and
propofol concentrations after a short propofol infusion in
an ovine model. Myburgh et al. (8) observed the same re-
lationship during longer propofol infusions in a high-CO
state induced by catecholamine infusion in the ovine. Ku-
rita et al. (5) confirmed, in a swine model, that Cp was in-
versely correlated with changes in CO during constant in-
fusion. We also plotted the relationship between measured
Cp and the inverse of CO, but we did not observe any sta-
tistical association. It must be highlighted that most of
the published studies were performed in animal models,
with no studies in humans. Recently, Keyl et al. (4) found
that Schnider Pk model markedly underestimated Cp in
patients with impaired left ventricular function.
In phase II of our study, we found a statistical correla-
6 Anesth Pain Med. 2019; 9(5):e96829.
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Figure 5. Predicted (green line) and measured (blue line) propofol concentrations (µg.mL-1) at SP1, SP2 (phase II), and KC moment in both phases. KC, knee-chest; SP1, supine;
SP2, supine after the second reduction in propofol infusion.
tion between propofol infused volume until LOC and base-
line CO, showing that CO is a determinant to infer the ini-
tial concentrations of propofol for anesthesia induction
(14).
In the present study, we expected a correlation be-
tween propofol infused volume and CO fall. Comparing
both phases, propofol consumption (propofol infused vol-
ume) was much lower in phase II than in phase I (P = 0.034)
(Table 2). Also, patients in both phases did not show differ-
ences in BIS values and other parameters; thus we can con-
clude that patients in the KC position need lower propo-
fol concentrations. Nevertheless, propofol targeted reduc-
tions did not attenuate the CO fall when placing patients
in the KC position, as the authors previously hypothesized.
The results suggest that planned decrements in propofol
target Ce did not correspond to a decrease in Cm (Figure
5), as in phase II, after two reductions, the underestimation
increased at the KC moment.
Furthermore, hemodynamic changes should be
avoided in high-risk patients, even for short periods,
as they are associated with poor outcomes (21-23). The
present study also showed an important finding that even
in ASA 1 and 2 patients, significant HD changes may occur
after the KC position.
5.1. Limitations
The present study has several limitations. ANOVA was
quite comprehensive, with three measures compared in
each individual and between the two groups. However, re-
garding propofol concentrations, the sample size may be
considered small. The definition of the moments of data
analysis was a challenge. We defined a 10-minute period
stabilization following induction and KC positioning ac-
cording to the literature (10, 24). The fact that this was
a non-randomized study may be considered a limitation.
However, we needed data from the first phase to determine
the intervention in the second phase.
5.2. Conclusions
Our study showed that the measured propofol con-
centrations, after hemodynamic changes associated with
the KC position, were much higher than the values pre-
dicted by Schnider Pk model. Planned propofol reduc-
tions did not attenuate the underestimation error from
the Pk model. When placing patients in the KC position, BIS
values decreased and the measured propofol concentra-
tions increased. Our results suggest that the CO variation
was responsible for the pharmacokinetic phenomenon de-
scribed above. In high-risk patients placed in the KC po-
sition, anesthesiologists must be aware of these pharma-
cokinetic changes and, in addition to standard monitor-
ing, the use of depth of anesthesia and cardiac output
monitors may be considered. Further work is planned in
an educational area with a simulation program to prepare
surgical teams to a structured and careful approach for
these patients.
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